Pharmafile Logo

How smart spaces and real-time strategy transformed ASCO® 2025

August 19, 2025 | Congress, Inizio, oncology 

- PMLiVE

Nick Bellomo, Director of Technology and Engagement, Inizio Medical

ASCO® 2025 wasn’t just about oncology breakthroughs – it was also a showcase for how technology is redefining congress engagement. Supporting dozens of clients with hundreds of deliverables, Inizio had a front-row seat to innovations that are reshaping how healthcare professionals (HCPs) learn and interact.

Highlights from the floor:

  • LED walls reimagined: Once static displays, LED walls are now interactive storytelling tools. From gesture-responsive MOAs to live trial dashboards, these experiences empowered HCPs to navigate content at their own pace, boosting engagement and driving more meaningful conversations.

  • Real-time in-booth analytics: Inizio piloted offline analytics that delivered live insights without internet dependency. This allowed brands to refine content mid-show, optimize staff alignment, and deliver more targeted education – all during the congress, not weeks later.

Why it matters:
These shifts mark a broader transformation: moving from passive storytelling to responsive engagement, and from delayed insights to real-time adaptability. For HCPs, this means richer, more relevant learning. For brands, it means smarter strategies and more impactful outcomes.

At Inizio, the booth is no longer just a backdrop – it’s a catalyst for strategic engagement and patient-focused progress.

Read the full article authored by Nick here. Discover more in the on-demand webinar Beyond the booth: Big ideas, smart spaces & strategic insights from ASCO® 2025.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Interactive infographic: LATAM

An overview of the six most-commonly researched, largest pharma markets in Latin America

Immuno-oncology: The market opportunity for PD-1/PD-L1s

Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies,...

Case Study: Using ‘Journey to the Future’ projective techniques to understand evolving customer expectations

Our client was developing a portfolio of innovative treatments and was in the process of recruiting a sales force to support the promotion of this portfolio. Research was required to...

Pegasus scoops five ‘Consultancy’ wins, making 2016 a stellar year for the health comms consultancy

Pegasus, an Ashfield company, part of UDG Healthcare plc, last night scooped its fifth ‘consultancy’ award of the year at the PRCA Awards in London’s Park Lane where it secured...

Free Thinking – US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare

Our latest Free Thinking white paper explores the legacy of the Affordable Care Act and the future for healthcare

Pegasus crowned PR Week’s Specialist Consultancy of the Year, making a hat-trick of Consultancy wins in 2016!

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have been crowned Specialist Consultancy of the Year at this week’s prestigious PR Week Awards. The accolade tops...

Therapy Watch market snapshots

Therapy Watch is a ‘real-time’ syndicated market tracking tool that provides marketing teams, brand managers and market researchers with strategic and tactical market information. Run entirely online to ensure speed,...

Case Study: Private market opportunity for a travel vaccine

Our client needed exploratory research to determine the global opportunity for a new travel vaccine in the private market. It was crucial to determine:Which markets had the highest potential to...

Infographic: Conference Live

Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.